14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
GMOV vs GIND: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Goldman Sachs India Equity ETF (GIND) is the stronger overall head-to-head candidate over GMO US Value ETF (GMOV) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). GMOV carries a Unified Composite Score of 40.8/100 (SELL) at $31.16 (N/M Forward P/E, N/A operating margin), whereas GIND carries 47.1/100 (HOLD) at $25.98 (N/M Forward P/E, N/A operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GMOV vs GIND. Trailing 12-month operating profitability (GMOV N/A vs GIND N/A) and valuation multiples (GMOV N/M vs GIND N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GMOV vs GIND Key Questions & Quantitative Answers
As of Nov 20, 2026, Goldman Sachs India Equity ETF (GIND) is the stronger overall head-to-head candidate over GMO US Value ETF (GMOV) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). GMOV carries a Unified Composite Score of 40.8/100 (SELL) at $31.16 (N/M Forward P/E, N/A operating margin), whereas GIND carries 47.1/100 (HOLD) at $25.98 (N/M Forward P/E, N/A operating margin). Technically, GMOV sits in a Neutral phase (RSI 30.6, UNCLASSIFIED options structure) and GIND sits in a Neutral phase (RSI 71.6, UNCLASSIFIED options structure).
GMOV and GIND split Growth & Scale metrics: GMOV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GIND at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GMOV generates N/A in USD-normalized revenue versus N/A for GIND. In operating R&D and SG&A reinvestment, GMOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GIND.
GMOV and GIND trade at balanced relative valuation multiples. GMOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GIND trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GMOV (N/A ROE) versus GIND (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, GMOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.38β · 17% Vol realized risk). By comparison, GIND carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 18% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.